tbuckley/cabot-search huggingface dataset:
Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles
Authors: Tianxu Zhang, Guanyin Zhu, Boyao Lu, Zhiyong Qian, Qiang Peng
Journal: Medicinal Research Reviews (2020)

Abstract The interaction of nanoparticles (NPs) with proteins and the formation of protein corona in the biological fluids are of great interest and significance for drug delivery. In the past decade, the corona formation in the blood and its impacts on the in vitro and in vivo fate of NPs has been well investigated and reviewed. Recently, more and more attention is paid to the nano–protein interactions taking place in the gastrointestinal tract (GIT) between the orally administered NPs and the digestive enzymes. The enzyme corona formed in the GIT can significantly affect the properties, gastrointestinal transit, and oral absorption of NPs. Since oral delivery is the most preferred delivery route, comprehensively understanding the corona formation in the GIT and its impacts on oral delivery NPs are of great importance. Herein, we aim to summarize the recent updates on the nano–protein interactions between NPs and digestive enzymes, and launch an interesting discussion on the potentials of using the digestive enzyme corona for the colon targeted delivery.
Some care home residents may have died because of blanket DNR orders, says regulator
Authors: Clare Dyer
Journal: BMJ (2020)

Some care home residents may have died because of blanket DNR orders, says regulator Clare DyerSome care home residents were wrongly subjected to decisions ruling out attempts at cardiopulmonary resuscitation (CPR) in the early stages of the covid-19 pandemic, leading to potentially avoidable deaths, the Care Quality Commission (CQC) has concluded. 11 Care Quality Commission.Review of do not attempt cardiopulmonary resuscitation decisions during the covid-19 pandemic.Interim report.November 2020.www.cqc.
<i>The BMJ</i> appeal 2020-21: Independent Food Aid Network gives a voice to those determined to make a difference
Authors: Jane Feinmann
Journal: BMJ (2020)

<i>The BMJ</i>’s appeal this year will support the Independent Food Aid Network, a charity that has helped independent food banks and other community meal providers throughout the covid-19 pandemic, writes <b>Jane Feinmann</b>
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
Authors: Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Francesco Di Raimondo, Giuseppe Rossi, Mario Boccadoro, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pellegrino Musto, Pier Paolo Fattori, Piero Galieni, Sergio Morandi, Dino Amadori, Marco Gobbi, Bruno Rotoli, Salvatore Mirto, Antonio Lazzaro, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino
Journal: The Lancet Haematology (2020)
Ozone pollution: a ‘hidden’ environmental layer for athletes preparing for the Tokyo 2020 Olympics &amp; Paralympics
Authors: Gareth N Sandford, Trent Stellingwerff, Michael Stephen Koehle
Journal: British Journal of Sports Medicine (2020)

Environmental factors such as climate and pollution form a key part of major championship preparation.1 The Tokyo 2020 Olympic/Paralympic Games will present a unique combination of high thermal and ozone stressors. Japan has the highest levels of ozone in the Organisation for Economic Co-operation and Development; with annual peak values (65–73 ppb) aligning with the Olympic/Paralympic schedules (23 July to 5 September 2021).

Herein, we provide a synopsis of the effects and potential mitigating factors of air pollution on athlete health and performance. We integrate these recommendations with established guidelines on heat,1 to provide guidance for the 2020 Summer Olympic/Paralympic Games and beyond (figure 1).



Figure 1 
Summary of how to concurrently prepare to compete in the heat with high levels of ozone. An athlete performance and health checklist for science and medicine staff.



Air pollution is a heterogeneous combination of both particles and gases that varies by location, time and season. Ground level ozone is a gas pollutant resulting from a chemical reaction between nitrogen oxides and hydrocarbons in the presence of ultraviolet radiation.2 3 Due to ozone’s positive …
18079 Low-cost treatments for advanced or severe photoaging and field cancerization: A Brazilian experience
Authors: Luis Henrique Barbizan de Moura, Hélio Amante Miot, Juliana M. Sumita, Mayra Ianhez, Carolina Okada Zerbini Guimara~es, Edileia Bagatin
Journal: Journal of the American Academy of Dermatology (2020)
Targeting the Wnt/β-catenin signaling pathway in cancer
Authors: Ya Zhang, Xin Wang
Journal: Journal of Hematology & Oncology (2020)

The aberrant Wnt/β-catenin signaling pathway facilitates cancer stem cell renewal, cell proliferation and differentiation, thus exerting crucial roles in tumorigenesis and therapy response. Accumulated investigations highlight the therapeutic potential of agents targeting Wnt/β-catenin signaling in cancer. Wnt ligand/ receptor interface, β-catenin destruction complex and TCF/β-catenin transcription complex are key components of the cascade and have been targeted with interventions in preclinical and clinical evaluations. This scoping review aims at outlining the latest progress on the current approaches and perspectives of Wnt/β-catenin signaling pathway targeted therapy in various cancer types. Better understanding of the updates on the inhibitors, antagonists and activators of Wnt/β-catenin pathway rationalizes innovative strategies for personalized cancer treatment. Further investigations are warranted to confirm precise and secure targeted agents and achieve optimal use with clinical benefits in malignant diseases.
16880 Prevalence of mucocutaneous findings in an inception systemic lupus erythematosus cohort
Authors: Alba Cicero-Casarrubias, Lilly Esquivel-Pedraza, Silvia Mendez-Flores, Linda Garcia Hidalgo, Judith Domiminguez-Cherit, Juanita Romero-Diaz
Journal: Journal of the American Academy of Dermatology (2020)
The Role of Exercise in Management of Mental Health Disorders: An Integrative Review
Authors: Patrick J. Smith, Rhonda M. Merwin
Journal: Annual Review of Medicine (2020)

A large and growing body of evidence suggests that physical activity (PA) may hold therapeutic promise in the management of mental health disorders. Most evidence linking PA to mental health outcomes has focused on the effects of aerobic exercise training on depression, although a growing body of work supports the efficacy of both aerobic and resistance exercise paradigms in the treatment of anxiety and post-traumatic stress disorder. Despite abundant evidence linking PA and mental health, use of exercise training as a mental health treatment remains limited due to three important sources of uncertainty: (a) large individual differences in response to exercise treatment within multiple mental health domains; (b) the critical importance of sustained PA engagement, not always achieved, for therapeutic benefit; and (c) disagreement regarding the relative importance of putative therapeutic mechanisms. Our review of treatment data on exercise interventions and mental health outcomes focuses primarily on depression and anxiety within a health neuroscience framework. Within this conceptual framework, neurobiological and behavioral mechanisms may have additiveor synergistic influences on key cognitive and behavioral processes that influence mental health outcomes. We therefore highlight sources of treatment heterogeneity by integrating the critical influences of (a) neurobiological mechanisms enhancing neuroplasticity and (b) behavioral learning of self-regulatory skills. Understanding the interrelationships between dynamic neurobiological and behavioral mechanisms may help inform personalized mental health treatments and clarify why, and for whom, exercise improves mental health outcomes. The review concludes with recommendations for future studies leveraging individual differences to refine treatment approaches to optimize mental health benefits.
15174 Risk of ischemic heart disease in patients with hidradenitis suppurativa: Analysis of real-world data within a large, urban, Midwestern US dermatology patient population
Authors: Eran C. Gwillim, Jennifer J. Parker, Anna C. Figueiredo, David Pontes, Anne E. Laumann, Dennis P. West, Beatrice Nardone
Journal: Journal of the American Academy of Dermatology (2020)
Explaining the Unexplained Causes of Syncope: Are We There Yet?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Niraj Mehta, Maria Zildany Pinheiro Tavora, Carlos A. Morillo
Journal: Journal of the American College of Cardiology (2011)
“I guess the trans identity goes with other minority identities”: An intersectional exploration of the experiences of trans and non-binary parents living in the UK
Authors: Susie Bower-Brown, Sophie Zadeh
Journal: International Journal of Transgender Health (2020)

Background: Research on trans and non-binary parents has identified challenges in integrating parenting and gender identities, and in navigating stigmatizing environments. Studies have also highlighted the unique experience of transmasculine pregnancy and its violation of cisheteronormative ideals, yet little is known about either the experiences of trans and non-binary parents who have used diverse routes to parenthood or their experiences beyond the transition to parenthood. Research on the way in which gender intersects with other identity categories to shape the experiences of trans and non-binary parents is also lacking.Aims: This study aimed to explore the experiences of trans and non-binary parents in the UK within different parenting spaces both during and after the transition to parenthood, using an intersectional framework.Methods: Eleven semi-structured interviews were conducted with trans and non-binary parents and analyzed according to the principles of thematic analysis.Results: Three main themes were identified, reflecting participants’ experiences within the “highly normative world” of parenting, and the strategies of “being a pragmatic parent” and “being a pioneering parent” used to navigate this.Discussion: The findings of this study highlight the usefulness of an intersectional approach for research on this topic. Findings also evidence a need for inclusive, and queer, parenting spaces for trans and non-binary parents, so that parents and children can enjoy the benefits of trans parenting.
Common variants in signaling transcription-factor-binding sites drive phenotypic variability in red blood cell traits
Authors: Avik Choudhuri, Eirini Trompouki, Brian J. Abraham, Leandro M. Colli, Kian Hong Kock, William Mallard, Min-Lee Yang, Divya S. Vinjamur, Alireza Ghamari, Audrey Sporrij, Karen Hoi, Barbara Hummel, Sonja Boatman, Victoria Chan, Sierra Tseng, Satish K. Nandakumar, Song Yang, Asher Lichtig, Michael Superdock, Seraj N. Grimes, Teresa V. Bowman, Yi Zhou, Shinichiro Takahashi, Roby Joehanes, Alan B. Cantor, Daniel E. Bauer, Santhi K. Ganesh, John Rinn, Paul S. Albert, Martha L. Bulyk, Stephen J. Chanock, Richard A. Young, Leonard I. Zon
Journal: Nature Genetics (2020)
17817 Prospective observational study to evaluate the benefits for the patient associated with the treatment of plaque psoriasis with apremilast after other systemic treatments in conditions of clinical practice in Spain (APPROPRIATE study)
Authors: Pablo de la Cueva Dobao, Susana Armesto Alonso, Mar Llamas-Velasco, Raquel Rivera, José-Manuel Carrascosa, Encarna Montesinos, Mercedes Gonzalez, Mariano Ara-Martin, Carmen García Calvo, Luis Puig
Journal: Journal of the American Academy of Dermatology (2020)
197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Authors: S. Qin, J. Tabernero, E. van Cutsem, C.S. Fuchs, Y.Y. Janjigian, P. Bhagia, K. Li, D. Adelberg, Y-J. Bang
Journal: Annals of Oncology (2020)
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Authors: Daniel V.T. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan F. Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran Turaga, Kevin Roggin, Mitchell C. Posner, Paul Chang, Sunil Narula, Murtuza Rampurwala, Yuan Ji, Theodore Karrison, Chih-Yi Liao, Blase N. Polite, Hedy L. Kindler
Journal: Cancer Discovery (2020)

The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and <12 months, respectively. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled with infrequent incidence of some biomarkers, has resulted in stalled therapeutic progress. We hypothesized that a personalized treatment strategy, applied at first diagnosis then serially over up to three treatment lines using monoclonal antibodies combined with optimally sequenced chemotherapy, could contend with these hurdles. This was tested using a novel clinical expansion-platform type II design with a survival primary endpoint. Of 68 patients by intention-to-treat, the one-year survival rate was 66% and mOS was 15.7 months, meeting the primary efficacy endpoint (one-sided P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 months) were superior to historical controls. The PANGEA strategy led to improved outcomes warranting a larger randomized study. SIGNIFICANCE: This study highlights excellent outcomes achieved by individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies at baseline and over time for GEA. Testing a predefined treatment strategy resulted in improved outcomes versus historical controls. Therapeutic resistance observed in correlative analyses suggests that dual targeted inhibition may be beneficial.This article is highlighted in the In This Issue feature, p. 211.
16306 Effect of concomitant medications on efficacy of sonidegib 200 mg daily in patients with locally advanced basal cell carcinoma: Results of the 42-month randomized, double-blind BOLT study
Authors: Reinhard Dummer, Michael R. Migden, Nicholas A. Squittieri, Li Liu, Alexander Guminski, John Lear
Journal: Journal of the American Academy of Dermatology (2020)
13632 Long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials
Authors: Peter C. van de Kerkhof, Esteban Daudén, Ignasi Pau-Charles, Andreu Schoenenberger López, Richard Langley
Journal: Journal of the American Academy of Dermatology (2020)
Left Ventricular Ejection Fraction in Addition to N-Terminal Pro–B-Type Natriuretic Peptide for Risk Stratification in the Ambulant Elderly: Get the Picture…or Not?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: A. Mark Richards
Journal: Journal of the American College of Cardiology (2011)
17899 Pain and Itch Are Dual Burdens in Hidradenitis Suppurativa
Authors: Kyla Price, Omar Rizvi, Jennifer M. Fernandez, Aleksi J. Hendricks, Kendra D. Marr, Elizabeth Mata, Alyssa Thompson, Melody Maarouf, Catherine M. Ludwig, Jennifer L. Hsiao, Vivian Shi
Journal: Journal of the American Academy of Dermatology (2020)
15416 Long-term effect of dupilumab with concomitant topical corticosteroids on the Patient-Oriented Eczema Measure in Adults with moderate to severe atopic dermatitis: LIBERTY AD CHRONOS trial
Authors: Jonathan I. Silverberg, Benjamin Lockshin, Melinda Gooderham, Zhen Chen, Abhijit Gadkari, Laurent Eckert, Ana Beatris Rossi
Journal: Journal of the American Academy of Dermatology (2020)
Abstract PO-070: What kills patients with severe Covid-19 might also kill patients with terminal cancer
Authors: Lingbing Zhang
Journal: Clinical Cancer Research (2020)

Abstract Introduction: As a prominent clinical feature of severe Covid-19, cytokine storm has attracted enormous attention recently. It is generally believed that cytokine storm might be the underlying force leading to health exacerbation and death from severe Covid-19. However, the role of cytokine storm in terminal cancer has not been reported. In this study, we investigated the role of cytokine storm in a murine tumor model that mimics the disease progression of terminal cancer. We found that cytokine storm develops in terminal cancer and leads to cachexia, which is a prevalent and lethal syndrome of terminal cancer. Methods: 7-week old BALB/c mice were inoculated with 1 x106 C26 tumor cells subcutaneously. Mice body weight and health condition were monitored starting 7 days after tumor inoculation. At various time points, serum cytokines were measured, immune cells were analyzed with flow cytometry, and multiple organs were collected and processed for histopathologic assessment. Results: Growth of subcutaneously inoculated tumors without metastasis progressively induces host body weight loss and overall health deterioration. Cytokine storm characterized by elevated expression of multiple proinflammatory cytokines such as IL-1, IL-6, and TNF-a in blood develops accompanying the health deterioration. In parallel with cytokine storm development, massive infiltration of Gr-1 positive cells occurs in vital organs (lung and liver) and brings severe tissue damage. Histopathologic check ruled out any tumor metastasis to these organs, which suggests that the inflammatory response is the cause of the multiple organ damage. Importantly, suppression of the inflammatory response with interventions can completely reverse the cachexia syndrome and increase survival. Conclusions and Implication: Cytokine storm develops and plays an important role in the health exacerbation of terminal cancer. Therefore, calming the cytokine storm with interventions that can suppress the inflammatory response might represent a new and promising approach to the treatment of terminal cancer. This approach may have the potential to save many patients from imminent deaths, which are often not directly caused by organ occupation. Citation Format: Lingbing Zhang. What kills patients with severe Covid-19 might also kill patients with terminal cancer [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2020 Jul 20-22. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(18_Suppl):Abstract nr PO-070.
Abstract IA11: AYA lymphomas: Bridging the divide
Authors: Kara Kelly
Journal: Blood Cancer Discovery (2020)

Abstract Lymphomas account for approximately 20-25% of annual cancer diagnoses in the adolescent and young adult (AYA) population, defined as ages 15–39 years. Despite continued improvements in lymphoma outcomes, AYAs have not exhibited survival gains to the same extent as other age groups. At present, this survival gap is a manifestation of many compounding factors including a lack of sufficient understanding of the tumor biology or the optimal therapeutic approaches, as well as delays in diagnosis, the supportive care needs, long-term toxicity risk, developmental stage of the AYA, and socioeconomic factors. There is no established standard of care for AYA lymphomas, and there is significant divergence in treatment approaches between medical and pediatric oncology. Data on the heterogeneity of lymphoid malignancies in the AYA population as compared with younger pediatric and older adult groups will be reviewed. The highest proportion (35-70%) of lymphoid malignancies are due to Hodgkin lymphoma and lymphoblastic leukemia/lymphoma, followed by diffuse large B-cell lymphoma (10%-20%). Sex, race, and ethnic differences in the AYA lymphomas are also observed. These findings suggest that AYA lymphomas are biologically distinct from those present in the pediatric and adult populations. Factors that may contribute to the observed age-based variation in disease include evolution of the immune system with age, changes in the impact of genetic susceptibility, and viral and/or environmental exposures. There is a marked difference between the pediatric and adult approaches for AYA lymphomas. The example of AYA Hodgkin lymphoma will be reviewed. The pediatric backbone chemotherapy regimen has been doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC), whereas the adult regimen has been doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Radiation therapy is incorporated more often in pediatric high-risk regimens and adult low-risk approaches. Because disease biology does not conform to an 18-year-old cutoff, which of these approaches is most appropriate for AYAs has not been established. Treatment approach is not standard and is often driven by the experience of the physician. Recent progress in developing collaborative clinical trials through the North American National Clinical Trials Network will be reviewed. Citation Format: Kara Kelly. AYA lymphomas: Bridging the divide [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr IA11.
13876 Achieving a PASI 50 at 2 weeks was associated with better long-term clinical outcomes and low discontinuation: A subgroup analysis of a phase 3 trial of ixekizumab and etanercept in moderate to severe psoriasis
Authors: David Rosmarin, David Shrom, Russel Burge, Kyoungah See, Missy McKean-Matthews, Terri Ridenour
Journal: Journal of the American Academy of Dermatology (2020)
214P Study of treatment outcome in adults with TFE related RCC
Authors: A. Singh, A. Joshi, V. Noronha, V. Patil, N. Menon, A. Kapoor, N. Menon, K. Prabhash, G. Bakshi, G. Prakash, M. Pal, P. Popat
Journal: Annals of Oncology (2020)